Scientists reverse Alzheimer’s in mice and restore memory

A University Hospitals-led study published Dec. 22 in Cell Reports Medicine reports that restoring brain NAD+ with the pharmacologic agent P7C3-A20 fully reversed advanced Alzheimer’s pathology and cognitive deficits in two genetically engineered mouse models and normalized the blood biomarker p-tau217. Results reproduce across models and human tissue analyses and the technology is being commercialized by Glengary Brain Health, but findings remain preclinical and investigators stress careful, controlled human trials are required before any clinical or commercial impact can be assumed.

Analysis

Market structure: Winners in a credible NAD+-restoration pathway are diagnostic/bioassay platforms and CROs that run large CNS trials (e.g., Quanterix QTRX, IQVIA IQV, ICON ICLR) plus early-stage small-molecule biotechs with CNS energy/metabolism programs (private or acquisitive targets). Large biologic/amyloid incumbents (Biogen BIIB, Eli Lilly LLY) face potential long-term pressure on pricing power for chronic infusions if an oral/small-molecule restorative proves effective, but near-term revenue risk is limited until human POC is shown. Pricing dynamics: successful human data would shift R&D spend toward CNS small molecules and diagnostics, tightening demand for trial capacity and raising CRO pricing 10–30% over 12–24 months.

Risk assessment: High-impact tail risks include human translational failure, oncogenic safety signals (NAD+ over-boosting), or supplement-driven adverse events that trigger regulatory crackdowns; probability material within 12–36 months. Immediate market risk (days–weeks) is limited to sentiment spikes; short term (3–12 months) hinges on IND/Phase 1 readouts and licensing/partnership announcements; long-term (1–5 years) depends on Phase 2/3 efficacy and payer reimbursement. Hidden dependencies: blood–brain barrier delivery, biomarker (p‑tau217) correlation with clinical outcomes, and IP/licensing control of P7C3-A20 or similar scaffolds.

Trade implications: Favor tactical exposure to CROs/diagnostics—establish 1–2% long IQV and 0.5–1% long QTRX sized to portfolio risk tolerance, target 25–50% upside on accelerated trial demand over 6–18 months, stop-loss 12%. Use options to manage binary risk: buy 9–12 month call spreads on QTRX (30–50% OTM) sized 0.5% and finance with short near-term calls to reduce premium. Pair trade: long IQV (trial services) vs short 0.5–1% of BIIB or LLY if those names trade >10% above historical EV/Revenue multiple and no new catalyst is announced within 12 months. Allocate 0.5–1% to venture/private rounds for NAD+ assets only after IP and IND clearance are confirmed (watch next 6–12 months).

Contrarian view: Consensus underestimates the near-term commercial upside to p‑tau217 diagnostics—if validated in humans, assay volumes could grow 2–3x in 18 months, favoring QTRX-like platforms. Conversely, the market may overprice preclinical success into small R&D-stage biotechs; historical Alzheimer hype cycles show many preclinical mechanisms fail in human POC, so maintain tight sizing and strict catalyst triggers. Unintended consequences: rapid retail adoption of NAD+ supplements could produce adverse-event headlines and regulatory bans that hurt both supplement sellers and the therapeutic narrative; set explicit cut-loss triggers at the first credible safety signal.

Key Decisions for Investors

• Establish a 1.5% long position in IQVIA (IQV) and a 0.75% long position in Quanterix (QTRX) over the next 30 days to capture increased trial/assay demand; target 25–50% upside within 6–18 months, set a 12% stop-loss on each name.
• Buy 9–12 month call spreads on QTRX sized to 0.5% of portfolio (buy 30–50% OTM calls, sell higher strikes to finance) to capture binary Phase 1/POC upside; close if no biomarker (p‑tau217) signal or IND announcement within 12 months.
• Reduce exposure to large-cap Alzheimer/amyloid plays (Biogen BIIB, Eli Lilly LLY) by 1–2% aggregate if either trades >10% premium to 12‑month historical EV/Revenue and redeploy proceeds to CRO/diagnostics names (IQV, ICLR, QTRX) over a 3‑month window.
• Allocate 0.5–1% to selective private/venture exposure in NAD+/mitochondrial CNS programs only after verifying licensing of P7C3‑A20 or IND filing; pursue deals on 12–18 month timelines and insist on p‑tau217 biomarker endpoints in trial design.